Madrigal expands MASH strategy as first Ribo siRNA candidate enters IND preparation
Discover why Ribo and Madrigal’s first nominated siRNA candidate could reshape genetically targeted and combination treatment strategies in MASH.
Pharma & Biotech
Pharma & Biotech
Ribo’s coronary artery disease filing highlights the next frontier for RNA-based cardiovascular drugs
Ribo’s RBD1119 Phase 2 filing could test whether siRNA drugs can reduce coronary artery disease risk without bleeding trade-offs.
Pharma & Biotech
Arrowhead just unlocked Australia for REDEMPLO, but the bigger RNAi test starts now
Arrowhead has regulatory momentum in rare lipid disease. The harder test is turning REDEMPLO approval into durable global uptake.
Pharma & Biotech
Can Sarepta Therapeutics prove RNA interference works in FSHD1 and DM1 with early Phase 1/2 data
Read why Sarepta Therapeutics’ first siRNA data in FSHD1 and DM1 could matter for rare disease drug development and investor sentiment.
Pharma & Biotech
Is insitro’s TherML platform finally delivering on the AI-native promise for biologics and small molecules?
insitro has announced the acquisition of CombinAbleAI and launched its new TherML platform, a modality-agnostic, AI-powered system that integrates small molecules, oligonucleotides, and biologics into a unified therapeutic design stack. The move signals a strategic attempt to industrialize AI-native drug discovery across modalities while reducing late-stage attrition risks. What makes this acquisition different from typical